Saturday, March 15, 2025
spot_img

Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025:

  • The 37th Annual Roth Conference is being held on March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. On March 17th, management will host one-on-one meetings and is scheduled for a Fireside Chat on the same day starting at 10 a.m. PT (1:00 p.m. ET). The live webcast is available on HBIO’s website at https://investor.harvardbioscience.com/events-and-presentations. Investors interested in scheduling a one-on-one meeting can contact [email protected].
  • The KeyBanc Capital Markets Healthcare Forum is a virtual event scheduled for March 19, 2025. Management will host one-on-one meetings and is also scheduled for a Fireside Chat with Paul Knight, KeyBanc Capital Markets, on the same day starting at 3:45 p.m. ET. The live webcast is available on HBIO’s website at https://investor.harvardbioscience.com/events-and-presentations. Investors interested in scheduling a one-on-one meeting can contact [email protected].

About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world. For more information, please visit our website at www.harvardbioscience.com 

Company Contact: 
Harvard Bioscience 
Jennifer Cote, Chief Financial Officer 
(508) 893-3120 

Investor Contacts: 
Three Part Advisors 
Sandy Martin / Erol Girgin
[email protected] 
(214) 616-2207 

Powered by SlickText.com

Hot this week

zSpace to Attend the 37th Annual Roth Conference

SAN JOSE, Calif., March 14, 2025 (GLOBE...

NAV announcement

Albion Technology & General VCT PLC LEI Code 213800TKJUY376H3KN16NAV...

NAV announcement

Albion Enterprise VCT PLC LEI Code 213800OVSRDHRJBMO720 NAV announcement...

Albion Crown VCT PLC: Half-yearly Financial Report

Albion Crown VCT PLC LEI Number: 213800SYIQPA3L3T1Q6814 March 2025...

Topics

zSpace to Attend the 37th Annual Roth Conference

SAN JOSE, Calif., March 14, 2025 (GLOBE...

NAV announcement

Albion Technology & General VCT PLC LEI Code 213800TKJUY376H3KN16NAV...

NAV announcement

Albion Enterprise VCT PLC LEI Code 213800OVSRDHRJBMO720 NAV announcement...

Albion Crown VCT PLC: Half-yearly Financial Report

Albion Crown VCT PLC LEI Number: 213800SYIQPA3L3T1Q6814 March 2025...

Ascot Announces Closing of the First Tranche of Private Placement

Not for distribution to U.S. news wire services or...

Heartland Express, Inc. Declares Regular Quarterly Dividend

NORTH LIBERTY, Iowa, March 14, 2025 (GLOBE...
spot_img

Related Articles

Popular Categories

spot_img